Joined February 2015
28 Photos and videos
Preeti Narayan, MD retweeted
#FDA approves a treatment for unresectable or metastatic HER2-positive breast cancer. ow.ly/gApl50XJP1c
11
15
4,703
Preeti Narayan, MD retweeted
Unfortunately, other obligations kept me and @JaniceTNBCmets from attending our favorite @abreastcancer session with the FDA, but nothing could keep us from at least saying hi to some of our favorite @FDAOncology people! @tmprowell #SABCS24
5
23
4,098
Preeti Narayan, MD retweeted
FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer. fda.gov/drugs/resources-info… #OCENewsBurst
1
15
15
9,656
Preeti Narayan, MD retweeted
What are pragmatic clinical trials? Clinical trials that streamline data collection and design by collecting only necessary information to answer the research question. A thread 🧵 1/5 #ProjectPragmatica #OCEProject5in5 #PragmaticTrials
2
45
78
16,015
Preeti Narayan, MD retweeted
“Dose is the foundation of drug development. Having the wrong dose is like building a house on quicksand.” @realrickpazdur, quoted by @pre_ryan at @NBCCStopBC’s #NBCCSummit.
1
9
27
1,389
Preeti Narayan, MD retweeted
Today’s #NBCCSummit panel includes @theNCI’s Larissa Korde, @pre_ryan, NBCC team leader Nicole Seagriff, and @QueensGlobalOnc’s Brooke Wilson about why oncology research should be designed to answer questions about outcomes and questions that matter for patients.
1
3
6
575
Mentioned this OCE initiative at @NBCCStopBC Advocate summit today at the outcomes that matter panel discussion, please post any ideas for pragmatic designs! @FDAOncology @drjennifergao @DrKNorsworthy @StevenClarkCunn @DrDonnaRivera
What is FDA Oncology's Project 5 in 5? ⏩ OCE Director Dr. Richard Pazdur explains how 𝘆𝗼𝘂 can take part in crowdsourcing to ultimately select 5 clinically relevant questions to be answered in pragmatic clinical trials. shareyourvoice.ideascalegov.… #OCEProject5in5
1
3
7
764
Preeti Narayan, MD retweeted
🎇 Today, Sunday, May 5 - #CincodeMayo - We officially launch Project 5 in 5: Crowdsourcing 5 clinically relevant questions for 5 pragmatic clinical trials! 💡 What's your clinical trial idea? Sign up and submit ideas here ➡️ shareyourvoice.ideascalegov.… #OCEProject5in5
1
7
13
3,644
Preeti Narayan, MD retweeted
✨Perfect day spending time with colleagues and friends ✨@FDAOncology
1
18
958
Preeti Narayan, MD retweeted
I want to say I appreciate @FDAOncology coming out from behind the curtain and discussing with patients and clinicians their thoughts & rationale around recent approvals. Great session, @SABCSSanAntonio 👏🏻
4
11
58
9,747
Preeti Narayan, MD retweeted
The latest episode of #OCEProjectLivinLabel - fam-Trastuzumab Deruxtecan-nxki: The Backstory – is now available! Watch the episode and read the labeling to receive free CME credit offered by @AACR. Click here 🔽 aacr.org/professionals/polic… @pre_ryan #OCEProjectSocrates
2
7
1,415
Preeti Narayan, MD retweeted
#SABCS23 Day 1 Highlights #CommunityOnc: @FDAOncology Review on recent approvals 1. #CAPItello291 2. #EMERALD 3. #TDxD 4. Tumor Agnostic landscape 5. Post CDK4/6i HR @SABCSSanAntonio @VivekSubbiah @VKaklamani @JaniceTNBCmets #bcsm @DrSGraff @oreganruth 1/6
2
38
104
16,099
Preeti Narayan, MD retweeted
Great start at #SABCS23 with the session on New approval in metastatic #breastcancer 🔸Elacestrant 🔸T-DXd 🔸Capivasertib Happening now at Hemisfair Ballroom 1-2 @SABCSSanAntonio @OncoAlert
6
18
1,651
Preeti Narayan, MD retweeted
FDA approved capivasertib with fulvestrant for HR HER2-neg locally advanced/metastatic breast cancer with PIK3CA/AKT1/PTEN alterations following progression on endocrine-based regimen or recurrence on completing adjuvant therapy fda.gov/drugs/resources-info… Click to #OCENewsBurst ⬆️
10
14
9,494
Preeti Narayan, MD retweeted
Today FDA approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for primary advanced or recurrent dMMR or MSI-H endometrial cancer. fda.gov/drugs/drug-approvals…
1
16
28
7,966
Important article for the oncology community on drug shortages and FDA's role, root causes for these shortages, and strategies to address -link is open access @OncoAlert
Read an interview with OCE Director Richard Pazdur about causes of oncology drug shortages and what the FDA can and can't do to fix it, via @TheCancerLetter open access article.
5
12
4,686
Preeti Narayan, MD retweeted
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer. First author Dr Preeti Narayan @pre_ryan, last author Dr Laleh Amiri-Kordestani @LalehAmiri. #OCEPublications pubmed.ncbi.nlm.nih.gov/3678…
1
4
11
2,217
Preeti Narayan, MD retweeted
6 Dec 2022
Don’t miss the GRASP-SABCS Reception happening in 20 MINUTES from 6-7:30pm in Room 220 (Cantilever Room)! Clinicians, researchers, and advocates are all invited!! #SABCS22
2
4
40
Approved today, T-DXd for tx of adult patients with unresectable or metastatic HER2 low (IHC 1 or IHC 2 /ISH-) breast cancer who have received a prior chemo in the metastatic setting or developed disease recurrence during or within 6 months of adj chemo. Details below #bcsm
Today, FDA approved Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2-low breast cancer, a newly defined subset of HER2-negative breast cancer. This is the first drug approved to treat this subtype. thread 1/3 #bcsm fda.gov/news-events/press-an…
4